乳がん患者の治療におけるラパチニブジトシル酸塩、トラスツズマブ、パクリタキセル、および手術

基本情報

NCT ID

NCT01688609

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

18

治験依頼者名

National Cancer Institute (NCI)

概要

This phase II trial studies how well giving lapatinib ditosylate together with trastuzumab, paclitaxel, and surgery works in treating patients with breast cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)